公开(公告)号：US20200318068A1

公开(公告)日：2020-10-08

申请号：US16839881

申请日：2020-04-03

Applicant: Immatics US, Inc.

Inventor： Thorsten DEMBERG

IPC: C12N5/0783 ,  C07K16/28 ,  A61K35/17

Abstract: The present disclosure generally relates to methods of improving T cell homing to organs or tissues by utilizing compounds and compositions, for example, retinoic acid receptor agonists. In an aspect, the disclosure provides for organ-homing engineered T cells for treating diseases, associated compositions, and methods for preparing thereof.

公开(公告)号：US20190292520A1

公开(公告)日：2019-09-26

申请号：US16361043

申请日：2019-03-21

Applicant: Immatics US, Inc.

Inventor： Amir Alpert

IPC: C12N5/0783 ,  A61K35/17 ,  A61P35/00

Abstract: The present disclosure provides for methods of improving the efficacy of T cells. In an aspect, the disclosure further provides for methods of enhancing the persistence of T cells for adoptive cell transfer or therapy (ACT). Cytokine sensitivity assays (CSA) and associated methodology capable of predicting the persistence of adoptively infused T Cells are further provided for by way of the instant disclosure. The disclosure also provides for methods of treating cancer in a subject in need thereof as well as T cells populations produced by methods described herein.

公开(公告)号：US20190216852A1

公开(公告)日：2019-07-18

申请号：US16250679

申请日：2019-01-17

Applicant: Immatics US, Inc.

Inventor： Mamta KALRA ,  Agathe BOURGOGNE ,  Ali MOHAMED ,  Steffen WALTER

IPC: A61K35/17 ,  C12N7/00 ,  C12N15/85 ,  A61P35/00

CPC classification number: A61K35/17 ,  A61P35/00 ,  C12N7/00 ,  C12N15/8509

Abstract: The present disclosure relates to T cells transduced with a viral vector at a volumetric concentration for immunotherapy and methods thereof. In another aspect, the present disclosure relates to the assessment of optimal lentiviral vector concentrations for transducing T cells. The present disclosure further provides for T cell populations produced by methods described herein.

公开(公告)号：US20250146019A1

公开(公告)日：2025-05-08

申请号：US19020283

申请日：2025-01-14

Applicant: Immatics US, Inc.

Inventor： Gagan BAJWA ,  Mamta KALRA ,  Melinda MATA

IPC: C12N15/86 ,  A61K40/11 ,  A61K40/32 ,  A61K40/42 ,  C07K14/705 ,  C07K14/725 ,  C12N5/0783

Abstract: The present disclosure relates to T cells capable of co-expressing T cell receptors (“TCR”) together with CD8 polypeptides and the use thereof in adoptive cellular therapy. The present disclosure further provides for modified CD8 sequences, vectors, and associated methods thereof.

公开(公告)号：US20250134931A1

公开(公告)日：2025-05-01

申请号：US18932062

申请日：2024-10-30

Applicant: IMMATICS US, INC.

Inventor： Justin GUNESCH ,  Mohammad HOSSAIN ,  Gagan BAJWA ,  Melinda MATA ,  Mamta KALRA

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C12N5/00 ,  C12N5/0783 ,  C12N15/86

Abstract: The present disclosure relates to cells capable of co-expressing T cell receptors (“TCR”) together with membrane-bound IL-15 polypeptides and/or CD8 polypeptides and the use thereof in adoptive cellular therapy. The present disclosure further provides for modified IL-15, IL-15Rα, IL-15/IL-15Rα fusion polypeptide, and IL-15Rα/IL-15 fusion polypeptide sequences, vectors, and associated methods of making and using the same. The present disclosure further provides for modified CD8 sequences, vectors, and associated methods of making and using the same.

公开(公告)号：US20250075230A1

公开(公告)日：2025-03-06

申请号：US18824203

申请日：2024-09-04

Applicant: Immatics US, Inc.

Inventor： Melinda MATA ,  Mamta KALRA ,  Yannick BULLIARD ,  Steffen WALTER ,  Ali MOHAMED

IPC: C12N15/86 ,  A61K39/00 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/10 ,  C12N15/113

Abstract: The present invention provides a mutated woodchuck post-transcriptional regulatory element (WPRE). In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.

公开(公告)号：US20250051418A1

公开(公告)日：2025-02-13

申请号：US18590008

申请日：2024-02-28

Applicant: Immatics US, Inc.

Inventor： Melinda MATA ,  Yannick BULLIARD ,  Mamta KALRA

IPC: C07K14/705 ,  A61K39/00 ,  C07K14/725 ,  C12N5/078 ,  C12N5/0783 ,  C12N15/64 ,  C12N15/86

Abstract: A vector containing a first nucleotide sequence S1 encoding a protein Z1, a second nucleotide sequence S2 encoding a protein Z2, a third nucleotide sequence S3 encoding a protein Y1, and a fourth nucleotide sequence S4 encoding a protein Y2, in which Z1 and Z2 form a first dimer and Y1 and Y2 form a second dimer, in which the first dimer Z1Z2 is different from the second dimer Y1Y2.

公开(公告)号：US20250019406A1

公开(公告)日：2025-01-16

申请号：US18889991

申请日：2024-09-19

Applicant: Immatics Biotechnologies GmbH ,  Immatics US, Inc.

Inventor： Sebastian BUNK ,  Dominik MAURER ,  Gisela SCHIMMACK ,  Heiko SCHUSTER ,  Claudia WAGNER ,  Sara YOUSEF ,  Amir ALPERT

IPC: C07K14/47 ,  A61K31/437 ,  A61K31/5383 ,  A61K35/17 ,  A61K35/76 ,  C07K14/725 ,  C12N5/0783 ,  G01N15/10 ,  G01N15/14 ,  G01N15/149 ,  G01N33/554

Abstract: The present invention relates to a method for selecting a cell or a virus expressing on its surface an antigen-binding protein specifically binding to a protein antigen of interest (PAI) while counter selection using a similar protein antigen (SPA) is applied. Further, the invention provides a method for determining the sequence of a nucleic acid encoding an antigen-binding protein or an antigen-binding part thereof and a method for producing a cell expressing a nucleic acid encoding an antigen-binding protein or an antigen-binding part thereof. The invention also relates to a method for treating a subject with a selected cell population.

公开(公告)号：US20240066127A1

公开(公告)日：2024-02-29

申请号：US18308427

申请日：2023-04-27

Applicant: IMMATICS US, INC.

Inventor： Justin GUNESCH ,  Melinda MATA ,  Mamta KALRA ,  Gagan BAJWA

IPC: A61K39/00 ,  A61K39/39 ,  A61P35/00 ,  C07K14/54 ,  C07K14/705 ,  C07K14/725

CPC classification number: A61K39/4635 ,  A61K39/39 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4632 ,  A61K39/464489 ,  A61P35/00 ,  C07K14/54 ,  C07K14/5434 ,  C07K14/5443 ,  C07K14/7051 ,  C07K14/70517 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55527 ,  A61K2039/55533 ,  A61K2039/55538 ,  A61K2039/55561

Abstract: The present disclosure relates to cells capable of co-expressing one or any combination of T cell receptors (“TCR”), CD8 polypeptides, interleukin 12 (IL-12) polypeptides, interleukin 15 (IL-15) polypeptides, and/or interleukin 18 (IL-18) polypeptides, and the use thereof in adoptive cellular therapy (“ACT”). The present disclosure further provides for modified CD8 sequences, IL-12 sequences, IL-15 sequences, IL-18 sequences, vectors, compositions, transformed T cells, and associated methods thereof.

公开(公告)号：US20190175650A1

公开(公告)日：2019-06-13

申请号：US16200308

申请日：2018-11-26

Applicant: Immatics US, Inc.

Inventor： Monique Dao ,  Steffen Walter ,  Melinda Mata ,  Aleksandra Nowicka ,  Yannick Bulliard

IPC: A61K35/17 ,  C12N5/0783 ,  C12N5/00 ,  C12N15/62 ,  A61K31/675 ,  A61K38/20 ,  C07K14/55 ,  C07K14/54 ,  C07K16/28 ,  A61K31/663 ,  C12N15/85

Abstract: The present disclosure relates to expansion and activation of T cells. In an aspect, the present disclosure relates to expansion and activation of γδ T cells that may be used for transgene expression. In another aspect, the disclosure relates to expansion and activation of γδ T cells while depleting α- and/or β-TCR positive cells. T cell populations comprising expanded γδ T cell and depleted or reduced α- and/or β-TCR positive cells are also provided for by the instant disclosure. The disclosure further provides for methods of using the disclosed T cell populations.